Treat QSI as a high-risk speculative stock: the company has minimal revenue, heavy cash burn, and a history of missed projections. Avoid or carefully limit exposure ahead of potential share dilution, which the host expects could occur in the coming weeks or months but has not been announced. Reassess QSI as Proteus approaches its delayed mid-2027 launch, weighing its $425,000 price and limited demonstrated capabilities against the host’s estimate that cash could run out around the same time. The discussion offers no actionable buy recommendation or price target for TMO.

Quantum-Si (QSI)

• Quantum-Si develops protein-sequencing instruments for pharmaceutical research and biomedical laboratories. Its core pitch is that its devices could provide a cheaper alternative to high-end mass spectrometers.
• The host is strongly bearish on the company and argues that its commercial performance has repeatedly fallen short:
  • Quantum-Si projected $104 million in revenue for 2024 and $186 million for 2025 in its 2021 SPAC presentation. The host says actual revenue was $3.1 million in 2024 and $2.5 million in 2025.
  • The company reportedly loses about $25 million per quarter and burned approximately $100 million over the prior 12 months.
• The host describes a pattern of promoting new devices after disappointing sales of earlier ones: Platinum, Platinum Pro, and now Proteus.
• The recent share-price rally followed company-reported interim data for Proteus. The host notes that Quantum-Si lists Proteus at $425,000, versus $85,000 for Platinum and $100,000 for Platinum Pro. Proteus was originally expected in late 2026 and, according to the transcript, was delayed to mid-2027.
• The host questions whether Proteus can deliver the company’s “democratization” pitch. In the host’s comparison, Proteus has been shown measuring 24 proteins at a time, while a Thermo Fisher mass spectrometer can measure more than 8,000. The host argues that Proteus may be cheaper than that high-end system, but still expensive and less capable.
• The transcript says Quantum-Si had a little over $100 million in cash at the end of Q2 2026. Based on its stated burn rate, the host estimates the company could run out of cash around mid-2027.
• The host expects another stock offering in the coming weeks or months, reasoning that the company needs cash and may take advantage of the recent share-price increase. This is the host’s prediction, not a confirmed announcement.
• The earlier late-2024 rally was linked to excitement about quantum-computing stocks. The host stresses that Quantum-Si’s business is in biomedical research, not quantum computing, and says the association with “quantum” in its name was coincidental.

Takeaways

• The discussion presents QSI as a high-risk, speculative stock, with minimal revenue, substantial cash burn, and a history of missed projections.
• Investors considering QSI should weigh the host’s concerns about Proteus’s price, capabilities, delayed launch, and the possibility of further share issuance and dilution.
• The transcript offers no price target. Its near-term timeline concerns are the anticipated Proteus launch in mid-2027 and the host’s estimate that cash could run out around mid-2027 absent additional funding.

Thermo Fisher Scientific (TMO)

• Thermo Fisher is discussed as a provider of a competing high-end mass spectrometer used for protein sequencing.
• The host says a relevant Thermo Fisher system costs approximately $1 million, can measure more than 8,000 proteins at a time, and offers broader capabilities than Proteus.
• The comparison is used to question whether Proteus can attract customers despite its lower stated price of $425,000.

Takeaways

• Thermo Fisher is presented as an established alternative in the protein-sequencing equipment market, but the transcript does not make a specific recommendation about TMO shares.
• The comparison highlights a potential trade-off for buyers: Proteus is described as less expensive than a high-end mass spectrometer, while the host argues it is also substantially less capable.

Protein-Sequencing Equipment

• The discussion focuses on demand for tools used in pharmaceutical research and biomedical laboratories.
• The potential opportunity is to make protein sequencing more accessible to smaller laboratories. The host argues that Quantum-Si’s earlier products did not establish that opportunity and doubts that Proteus will do so at its stated price.

Takeaways

• The transcript suggests evaluating equipment companies on actual customer demand, sales, product capabilities, and affordability, rather than product claims or market excitement alone.
• No broader sector recommendation or sector-wide price outlook is provided.